IO Biotech, Inc. (IOBT)

1.4800 -0.0500 (-3.27%) At close: 04:00PM EDT

IO Biotech, Inc.

Ole Maaløes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 29 80
https://www.iobiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 68

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mai-Britt Zocca Ph.D.	Founder, President, CEO, Principal Financial Officer & Director	892.24k	N/A	1968
Mr. Devin Whittemore Smith	Secretary, General Counsel & Chief Compliance Officer	621.8k	N/A	1968
Dr. Qasim Iftikhar Ahmad M.D.	Chief Medical Officer	503.28k	N/A	1971
Prof. Inge Marie Svane M.D., Ph.D.	Founder & Clinical Advisor	N/A	N/A	N/A
Prof. Mads Hald Andersen M.D., Ph.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Anders Ljungqvist	Founder	N/A	N/A	N/A
Prof. Per Thor Straten	Founder	N/A	N/A	N/A
Ms. Amy B. Sullivan M.B.A.	Chief Financial Officer	391.24k	N/A	1971
Mr. Eric Faulkner M.B.A.	Chief Technical Officer	N/A	N/A	N/A
Mr. Daniel G. Mannix Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Corporate governance

IO Biotech, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.